ID   UT-SCC-24A
AC   CVCL_7826
SY   UT-SCC 24A; University of Turku-Squamous Cell Carcinoma-24A
DR   BTO; BTO_0003722
DR   Cosmic; 1140778
DR   Cosmic; 1219862
DR   Cosmic; 1483464
DR   GEO; GSM2883363
DR   GEO; GSM2888826
DR   Wikidata; Q54992103
RX   DOI=10.1158/1538-7445.AM2020-507;
RX   PubMed=8725545;
RX   PubMed=16203773;
RX   PubMed=16331601;
RX   PubMed=17312569;
RX   PubMed=18487078;
RX   PubMed=29970484;
RX   PubMed=30135316;
RX   PubMed=33802339;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=16203773; PubMed=29970484; PubMed=33802339).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
ST   Source(s): PubMed=30135316; PubMed=33802339
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 12,14
ST   D16S539: 11
ST   D18S51: 18
ST   D19S433: 12,14.2
ST   D21S11: 29,30
ST   D2S1338: 19,20 (PubMed=30135316)
ST   D2S1338: 20 (PubMed=33802339)
ST   D3S1358: 16
ST   D5S818: 10
ST   D7S820: 8,11 (PubMed=30135316)
ST   D7S820: 11 (PubMed=33802339)
ST   D8S1179: 13,15
ST   FGA: 19,22
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 16,18
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7827 ! UT-SCC-24B
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 17
//
RX   DOI=10.1158/1538-7445.AM2020-507;
RA   Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J.,
RA   Koritzinsky M., Wouters B.G.;
RT   "Repurposing of FDA approved drugs for treatment of metastatic HNSCC.";
RL   Cancer Res. 80 Suppl. 16:507-507(2020).
//
RX   PubMed=8725545; DOI=10.3109/00016489609137854;
RA   Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.;
RT   "Increased radiosensitivity is associated with p53 mutations in cell
RT   lines derived from oral cavity carcinoma.";
RL   Acta Oto-Laryngol. 116:341-344(1996).
//
RX   PubMed=16203773; DOI=10.1158/1078-0432.CCR-05-0378;
RA   Mandic R., Schamberger C.J., Muller J.F., Geyer M., Zhu L.,
RA   Carey T.E., Grenman R., Dunne A.A., Werner J.A.;
RT   "Reduced cisplatin sensitivity of head and neck squamous cell
RT   carcinoma cell lines correlates with mutations affecting the
RT   COOH-terminal nuclear localization signal of p53.";
RL   Clin. Cancer Res. 11:6845-6852(2005).
//
RX   PubMed=16331601; DOI=10.1002/ijc.21514;
RA   Muller A., Sonkoly E., Eulert C., Gerber P.A., Kubitza R.,
RA   Schirlau K., Franken-Kunkel P., Poremba C., Snyderman C.H., Klotz L.-O.,
RA   Ruzicka T., Bier H., Zlotnik A., Whiteside T.L., Homey B.,
RA   Hoffmann T.K.;
RT   "Chemokine receptors in head and neck cancer: association with
RT   metastatic spread and regulation during chemotherapy.";
RL   Int. J. Cancer 118:2147-2157(2006).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=18487078; DOI=10.1016/j.oraloncology.2008.02.006;
RA   Hoffmann T.K., Sonkoly E., Hauser U., van Lierop A., Whiteside T.L.,
RA   Klussmann J.P., Hafner D., Schuler P.J., Friebe-Hoffmann U.,
RA   Scheckenbach K., Erjala K., Grenman R., Schipper J., Bier H.,
RA   Balz V.;
RT   "Alterations in the p53 pathway and their association with radio- and
RT   chemosensitivity in head and neck squamous cell carcinoma.";
RL   Oral Oncol. 44:1100-1109(2008).
//
RX   PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733;
RA   Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A.,
RA   Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M.,
RA   Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.;
RT   "Drug-sensitivity screening and genomic characterization of 45
RT   HPV-negative head and neck carcinoma cell lines for novel biomarkers
RT   of drug efficacy.";
RL   Mol. Cancer Ther. 17:2060-2071(2018).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//
RX   PubMed=33802339; DOI=10.3390/cancers13051069; PMCID=PMC7959143;
RA   Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.;
RT   "Genotyping and characterization of HPV status, hypoxia, and
RT   radiosensitivity in 22 head and neck cancer cell lines.";
RL   Cancers (Basel) 13:1069.1-1069.12(2021).
//